NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

XBiotech Inc. (XBIT) Stock Analysis

XBiotech Inc. (XBIT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XBIT

$2.20

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XBIT with… →

XBIT Key Statistics

As of Sep 4, 2026
Trading
Open
$2.20
Previous Close
$2.20
Day's Range
2.19–2.25
52-Week Range
2.09–3.44
Volume
118.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$67.07M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.48
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$45.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.49M
1-Year Return
−26.17%
Dividend and dates
Avg Volume
38.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XBIT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.95%
2025−39.49%
2024−1.25%
2023+13.96%
2022−68.46%
2021−17.46%
2020−16.15%
2019+267.42%
2018+28.93%
2017−61.07%
2016 (partial year)−35.54%

As of September 4, 2026.

XBIT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$45.54M—
2024$0.00−$38.53M—
2023$0.00−$24.56M—
2022$4.01M−$32.90M−820.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$55.69M−$45.54M—
2024$0.00—−$42.47M−$38.53M—
2023$0.00$0.00−$37.51M−$24.56M—
2022$4.01M$3.36M−$34.49M−$32.90M−820.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XBIT Valuation vs Biotechnology Median

Median of 656 stocks
MetricXBITBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

XBiotech Inc. (XBIT) carries a market capitalisation of $67.07M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 87.

Over the past 52 weeks the price has ranged from $2.09 to $3.44. XBIT last closed at $2.20 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 5.26% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $45.54M. The reported profit margin is 0%. Trailing earnings per share are −1.48.

Across the 4 fiscal years on file, revenue moves from $4.01M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 16.92.

The reported beta is 0.85. Daily returns over the trailing 10 years annualize to a volatility of 73.03%. Over the trailing twelve months the price has returned −26.17%. Across 10 years the annualized return works out at −15.20%.

Growth & Income

No dividend is on file for XBIT.

So far in 2026 the price is −7.95%. The strongest complete calendar year on file is 2019 at +267.42%; the weakest is 2022 at −68.46%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

XBiotech Inc. (XBIT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
XBiotech Inc. XBIT $67.07M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. XBiotech Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Visit website →